Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 February 2007Website:
http://www.madrigalpharma.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
MDGL Latest News
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
There's a bright future ahead for this company.
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allowance for non-invasive testing [NIT] enhance patient accessibility and Rezdiffra's adoption rate. Competition from Novo Nordisk's Semaglutide poses a market risk, but Rezdiffra's liver-specific mechanism offers a targeted advantage.
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego.
Madrigal Pharmaceuticals' Rezdiffra, approved for NASH, shows strong early demand and revenue growth, making Q3 earnings a potential catalyst for stock movement. Despite steep Q2 losses, Madrigal's $1.1B cash reserves and strategic execution position Rezdiffra as the market leader in NASH/MASH. Analysts forecast substantial revenue growth and narrowing losses for Madrigal, with expectations of profitability within a few years.
CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the MAESTRO-NASH OUTCOMES trial evaluating resmetirom for the treatment of patients with compensated NASH cirrhosis has completed enrollment.
What type of business is Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The corporation was registered in Delaware in September 2011. The headquarters is located in Pennsylvania. The company's main focus is on the drug MGL-3196 (resmetirom), which has the potential to be used for the treatment of a variety of liver conditions, including non-alcoholic steatohepatitis. Successful further development and final regulatory approval of resmetirom are crucial for the future success of Madrigal Pharmaceuticals, Inc.
What sector is Madrigal Pharmaceuticals in?
Madrigal Pharmaceuticals is in the Healthcare sector
What industry is Madrigal Pharmaceuticals in?
Madrigal Pharmaceuticals is in the Biotechnology industry
What country is Madrigal Pharmaceuticals from?
Madrigal Pharmaceuticals is headquartered in United States
When did Madrigal Pharmaceuticals go public?
Madrigal Pharmaceuticals initial public offering (IPO) was on 06 February 2007
What is Madrigal Pharmaceuticals website?
https://www.madrigalpharma.com
Is Madrigal Pharmaceuticals in the S&P 500?
No, Madrigal Pharmaceuticals is not included in the S&P 500 index
Is Madrigal Pharmaceuticals in the NASDAQ 100?
No, Madrigal Pharmaceuticals is not included in the NASDAQ 100 index
Is Madrigal Pharmaceuticals in the Dow Jones?
No, Madrigal Pharmaceuticals is not included in the Dow Jones index
When was Madrigal Pharmaceuticals the previous earnings report?
No data
When does Madrigal Pharmaceuticals earnings report?
The next expected earnings date for Madrigal Pharmaceuticals is 28 February 2025